PRESS RELEASE

Q2 2023 — Press release

Q2 2023PDF · 11 pages276 KB
News Release
____________________________________________________________________________
Merck Announces Second-Quarter 2023 Financial Results
- 	Sales Reflect Sustained Underlying Growth, Particularly in Oncology and Vaccines
- 	Total Worldwide Sales Were $15.0 Billion, an Increase of 3% From Second Quarter
2022; Excluding LAGEVRIO, Growth Was 11%; Excluding LAGEVRIO and the Impact of
Foreign Exchange, Growth Was 14%
o 	KEYTRUDA Sales Grew 19% to $6.3 Billion; Excluding the Impact of Foreign
Exchange, Sales Grew 21%
o 	GARDASIL/GARDASIL 9 Sales Grew 47% to $2.5 Billion; Excluding the Impact
of Foreign Exchange, Sales Grew 53%
o 	LAGEVRIO Sales Declined 83% to $203 Million; Excluding the Impact of Foreign
Exchange, Sales Declined 82%
- 	GAAP Loss per Share Was $2.35; Non-GAAP Loss per Share Was $2.06; GAAP and
Non-GAAP Loss per Share Include a Charge of $4.02 per Share for the Acquisition of
Prometheus
- 	Presented Compelling Data in Earlier Stages of Cancer at 2023 ASCO Annual Meeting,
Including:
o 	Positive Phase 3 Results From KEYNOTE-671 Trial
o 	Promising New Data From Phase 2b KEYNOTE-942/mRNA-4157-P201 Trial in
Collaboration With Moderna
- 	Announced Positive Results From Two Phase 3 Trials Evaluating V116
- 	Submitted Biologics License Application to the U.S. FDA for Sotatercept
- 	Full-Year 2023 Financial Outlook
o 	Raises and Narrows Expected Worldwide Sales Range To Be Between $58.6
Billion and $59.6 Billion, Including Negative Impact of Foreign Exchange of
Approximately 2 Percentage Points; Outlook Includes Approximately $1.0 Billion
of LAGEVRIO Sales
o 	Now Expects Non-GAAP EPS To Be Between $2.95 and $3.05, Including the
Negative Impact of Foreign Exchange of Approximately 5 Percentage Points;
Outlook Reflects Negative Impact From One-Time Charge of $10.2 Billion, or
$4.02 per Share, for the Acquisition of Prometheus
RAHWAY, N.J., Aug. 1, 2023 – Merck (NYSE: MRK), known as MSD outside the United States
and Canada, today announced financial results for the second quarter of 2023.
"We continue to make great progress as we advance our broad and deep pipeline, raise
the bar of innovation, and bring forward leading-edge science to save and improve lives around
the world," said Robert M. Davis, chairman and chief executive officer, Merck. "We delivered
robust underlying growth during the second quarter and are well positioned to achieve strong

-- 1 of 11 --

- 2 -
full-year results. I am proud of our talented, diverse and dedicated global team that continues to
focus on creating value for patients and all our stakeholders now and well into the future.”
Financial Summary
$ in millions, except EPS amounts
Second Quarter
2023 	2022 	Change
Change Ex-
Exchange
Sales 	$15,035 	$14,593 	3% 	7%
GAAP net (loss) income1 	(5,975) 	3,944 	**N/M 	N/M
Non-GAAP net (loss) income that excludes certain items 1,2* 	(5,220) 	4,743 	N/M 	N/M
GAAP EPS 	(2.35) 	1.55 	N/M 	N/M
Non-GAAP EPS that excludes certain items 2* 	(2.06) 	1.87 	N/M 	N/M
*Refer to table on page 6.
**Not meaningful
Generally Accepted Accounting Principles (GAAP) loss / earnings per share (EPS)
assuming dilution was a loss per share of $2.35 for the second quarter of 2023. Non-GAAP loss
per share was $2.06 for the second quarter of 2023. Both GAAP and non-GAAP loss per share
were due to a charge for the acquisition of Prometheus Biosciences, Inc. (Prometheus) of $4.02
per share. Additionally, both GAAP and non-GAAP loss per share in the second quarter of 2023
were unfavorably affected by lower sales of LAGEVRIO and the impact of foreign exchange
compared with the second quarter of 2022.
Non-GAAP EPS excludes acquisition- and divestiture-related costs and costs related to
restructuring programs, as well as income and losses from investments in equity securities.
Year-to-date results can be found in the attached tables.
1 Net (loss) income attributable to Merck & Co., Inc.
2 Merck is providing certain 2023 and 2022 non-GAAP information that excludes certain items because of the nature of these items
and the impact they have on the analysis of underlying business performance and trends. Management believes that providing this
information enhances investors’ understanding of the company’s results because management uses non-GAAP results to assess
performance. Management uses non-GAAP measures internally for planning and forecasting purposes and to measure the
performance of the company along with other metrics. In addition, senior management’s annual compensation is derived in part
using a non-GAAP pre-tax income metric. This information should be considered in addition to, but not as a substitute for or superior
to, information prepared in accordance with GAAP. For a description of the non-GAAP adjustments, see Table 2a attached to this
release.

-- 2 of 11 --

- 3 -
Second-Quarter Sales Performance
The following table reflects sales of the company’s top products and significant
performance drivers.
Second Quarter
$ in millions 	2023 	2022 	Change
Change
Ex-
Exchange 	Commentary
Total Sales 	$15,035 	$14,593 	3% 	7%
Pharmaceutical 	13,457 	12,756 	6% 	8%
Increase driven by growth in oncology,
vaccines and hospital acute care, partially
offset by lower sales in virology due to
LAGEVRIO, and in diabetes. Excluding
LAGEVRIO, growth of 14%. Excluding
LAGEVRIO and unfavorable impact of foreign
exchange, growth of 17%.
KEYTRUDA 	6,271 	5,252 	19% 	21%
Growth from continued strong global
momentum in metastatic indications, including
certain types of non-small cell lung cancer
(NSCLC), renal cell carcinoma (RCC), head
and neck squamous cell carcinoma and triple-
negative breast cancer (TNBC), and increased
uptake across earlier-stage indications,
including certain types of neoadjuvant/adjuvant
TNBC in the U.S.
GARDASIL /
GARDASIL 9 	2,458 	1,674 	47% 	53%
Growth largely due to strong global demand,
particularly in China.
JANUVIA / JANUMET 	864 	1,233 	-30% 	-28%
Decline primarily due to generic competition in
several international markets, particularly in
Europe, and lower demand and pricing in the
U.S.
PROQUAD, M-M-R II
and VARIVAX 	582 	578 	1% 	1% 	Relatively flat compared with prior year.
BRIDION 	502 	426 	18% 	19%
Growth primarily due to increased demand,
particularly in the U.S., reflecting an increase
in market share among neuromuscular
blockade reversal agents.
Lynparza* 	310 	275 	13% 	15%
Growth driven primarily by increased demand
in certain international markets.
Lenvima* 	242 	231 	5% 	6%
Growth primarily due to higher demand in the
U.S., partially offset by lower demand in China.
LAGEVRIO 	203 	1,177 	-83% 	-82%
Decrease largely attributable to lower sales in
Japan and nonrecurrence of sales in the U.K.
SIMPONI 	180 	181 	-1% 	-1% 	Relatively flat compared with prior year.
VAXNEUVANCE 	168 	12 	***N/M 	N/M
Growth driven largely by continued uptake in
pediatric indication following launch in the U.S.
Animal Health 	1,456 	1,467 	-1% 	2%
Excluding unfavorable impact of foreign
exchange, growth primarily driven by higher
pricing in both Livestock and Companion
Animal product portfolios.
Livestock 	807 	826 	-2% 	2%
Excluding unfavorable impact of foreign
exchange, growth due to higher pricing, as
well as higher demand for swine and poultry
products, partially offset by lower demand for
ruminant products, due in part to reduced herd
sizes.
Companion Animal 	649 	641 	1% 	2%
Growth driven by higher pricing, including for
the BRAVECTO line of products, partially
offset by supply challenges for certain
companion animal vaccines. Sales of

-- 3 of 11 --

- 4 -
Second Quarter
$ in millions 	2023 	2022 	Change
Change
Ex-
Exchange 	Commentary
BRAVECTO were $326 million and $309
million in the current and prior quarters,
respectively, which represented growth of 5%
or 7% excluding unfavorable impact of foreign
exchange.
Other Revenues** 	122 	370 	-67% 	-19%
Decline primarily due to impact of revenue
hedging. Excluding unfavorable impact of
foreign exchange, decline due to lower
royalties and milestone payments received for
out-licensing arrangements.
*Alliance revenue for this product represents Merck’s share of profits, which are product sales net of cost of sales and
commercialization costs.
**Other revenues are comprised primarily of revenues from third-party manufacturing arrangements and miscellaneous corporate
revenues, including revenue-hedging activities.
***Not meaningful
Second-Quarter Expense, EPS and Related Information
The table below presents selected expense information.
$ in millions 	GAAP
Acquisition-
and
Divestiture-
Related
Costs3
Restructuring
Costs
(Income)
Loss From
Investments
in Equity
Securities
Non-
GAAP2
Second Quarter 2023
Cost of sales 	$4,024 	$467 	$32 	$- 	$3,525
Selling, general and administrative 	2,702 	25 	52 	- 	2,625
Research and development 	13,321 	9 	1 	- 	13,311
Restructuring costs 	151 	- 	151 	- 	-
Other (income) expense, net 	172 	(3) 	- 	194 	(19)
Second Quarter 2022
Cost of sales 	$4,216 	$451 	$67 	$- 	$3,698
Selling, general and administrative 	2,512 	65 	27 	- 	2,420
Research and development 	2,798 	12 	22 	- 	2,764
Restructuring costs 	142 	- 	142 	- 	-
Other (income) expense, net 	438 	2 	- 	234 	202
GAAP Expense, EPS and Related Information
Gross margin was 73.2% for the second quarter of 2023 compared with 71.1% for the
second quarter of 2022. The increase was primarily due to lower LAGEVRIO sales, which have
a low gross margin, as well as the favorable impact of product mix. The gross margin increase
was partially offset by the unfavorable impact of foreign exchange.
Selling, general and administrative (SG&A) expenses were $2.7 billion in the second
quarter of 2023, an increase of 8% compared with the second quarter of 2022. The increase
3 Includes expenses for the amortization of intangible assets and purchase accounting adjustments to inventories recognized as a
result of acquisitions of businesses, intangible asset impairment charges and expense or income related to changes in the
estimated fair value measurement of liabilities for contingent consideration. Also includes integration, transaction and certain other
costs associated with acquisitions and divestitures, as well as amortization of intangible assets related to collaborations and
licensing arrangements.

-- 4 of 11 --

- 5 -
was primarily due to higher administrative costs, including higher compensation and benefit
costs, and higher promotional spending, partially offset by lower acquisition- and divestiture-
related costs and the favorable impact of foreign exchange.
Research and development (R&D) expenses were $13.3 billion in the second quarter of
2023 compared with $2.8 billion in the second quarter of 2022. The increase was primarily due
to a $10.2 billion charge for the acquisition of Prometheus. The remaining increase was driven
by higher compensation and benefit costs, reflecting in part increased headcount, higher
investments in discovery research and early drug development, and higher clinical development
spending.
Other (income) expense, net, was $172 million of expense in the second quarter of 2023
compared with $438 million of expense in the second quarter of 2022, primarily due to lower net
losses from investments in equity securities and lower pension settlement costs.
The income tax provision for the second quarter of 2023 was $637 million on a pretax
loss of $5.3 billion, resulting in an effective tax rate of (11.9)%. This effective tax rate includes a
25.1 percentage point unfavorable impact of the charge for the acquisition of Prometheus, for
which no tax benefit was recorded.
GAAP loss per share was $2.35 for the second quarter of 2023 compared with earnings
per share of $1.55 for the second quarter of 2022.
Non-GAAP Expense, EPS and Related Information
Non-GAAP gross margin was 76.6% for the second quarter of 2023 compared with
74.7% for the second quarter of 2022. The increase was primarily due to lower LAGEVRIO
sales, which have a low gross margin, as well as the favorable impact of product mix. The gross
margin increase was partially offset by the unfavorable impact of foreign exchange.
Non-GAAP SG&A expenses were $2.6 billion in the second quarter of 2023, an increase
of 8% compared with the second quarter of 2022. The increase was primarily due to higher
administrative costs, including higher compensation and benefit costs, and higher promotional
spending, partially offset by the favorable impact of foreign exchange.
Non-GAAP R&D expenses were $13.3 billion in the second quarter of 2023 compared
with $2.8 billion in the second quarter of 2022. The increase was primarily due to a $10.2 billion
charge for the acquisition of Prometheus. The remaining increase was driven by higher
compensation and benefit costs, reflecting in part increased headcount, higher investments in
discovery research and early drug development, and higher clinical development spending.
Non-GAAP other (income) expense, net, was $19 million of income in the second
quarter of 2023 compared with $202 million of expense in the second quarter of 2022, primarily
due to lower pension settlement costs.

-- 5 of 11 --

- 6 -
The non-GAAP income tax provision for the second quarter of 2023 was $810 million on
a pretax loss of $4.4 billion, resulting in a non-GAAP effective tax rate of (18.4)%. This effective
tax rate includes a 32.5 percentage point unfavorable impact of the charge for the acquisition of
Prometheus, for which no tax benefit was recorded.
Non-GAAP loss per share was $2.06 for the second quarter of 2023 compared with
earnings per share of $1.87 for the second quarter of 2022.
A reconciliation of GAAP to non-GAAP net (loss) income and EPS is provided in the
table that follows.
Pipeline and Portfolio Highlights
Merck’s expansive research efforts resulted in continued progress across its broad
pipeline and portfolio. In oncology, the company reached regulatory milestones across different
stages of cancer and shared positive results from a range of clinical trials. Notably, Merck
presented data on four approved medicines and two pipeline candidates in more than 25 types
of cancer at the 2023 American Society of Clinical Oncology (ASCO) Annual Meeting, including
investigational data for KEYTRUDA that demonstrates its progress in earlier stages of disease.
Further, in vaccines, Merck announced positive topline results demonstrating that V116,
an investigational 21-valent pneumococcal conjugate vaccine specifically designed for adults,
met key immunogenicity and safety endpoints in two Phase 3 trials. In cardiovascular, Merck
submitted a Biologics License Application to the U.S. Food and Drug Administration (FDA) for
sotatercept, Merck’s novel investigational activin signaling inhibitor for the treatment of adults
with pulmonary arterial hypertension (World Health Organization Group 1). In chronic cough,
Merck received an acceptance from the FDA for the resubmission of the New Drug Application
for gefapixant and assigned a target action date of Dec. 27, 2023.
Second Quarter
$ in millions, except EPS amounts 	2023 	2022
EPS
GAAP EPS 	$(2.35) 	$1.55
Difference 	0.29 	0.32
Non-GAAP EPS that excludes items listed below2 	$(2.06) 	$1.87
Net (Loss) Income
GAAP net (loss) income 1 	$(5,975) 	$3,944
Difference 	755 	799
Non-GAAP net (loss) income that excludes items listed below1,2 	$(5,220) 	$4,743
Excluded Items:
Acquisition- and divestiture-related costs 3 	$498 	$530
Restructuring costs 	236 	258
Loss from investments in equity securities 	194 	234
Increase to net loss / decrease to net income before taxes 	928 	1,022
Estimated income tax (benefit) expense 	(173) 	(223)
Increase to net loss / decrease to net income 	$755 	$799

-- 6 of 11 --

- 7 -
Merck also completed the acquisition of Prometheus, which will accelerate the
company’s growing presence in immunology and add diversity to its pipeline. Prometheus’
leading clinical candidate, MK-7240, formerly known as PRA-023, creates an opportunity for
Merck to transform the treatment of immune-mediated diseases.
Notable recent news releases on Merck’s pipeline and portfolio are provided in the table
that follows.
Oncology
FDA Approved Lynparza Plus Abiraterone and Prednisone or Prednisolone for
Treatment of Adult Patients With BRCA-Mutated Metastatic Castration-
Resistant Prostate Cancer
(Read
Announcement)
FDA Accepted Application for Merck’s KEYTRUDA Plus Chemotherapy as
Treatment for Advanced or Unresectable Biliary Tract Cancer
(Read
Announcement)
Merck’s KEYTRUDA Plus Chemotherapy Before Surgery and Continued as a
Single Agent After Surgery Reduced the Risk of Event-Free Survival Events
by 42% Versus Pre-Operative Chemotherapy in Resectable Stage II, IIIA or
IIIB NSCLC
(Read
Announcement)
Merck and Moderna Initiated Phase 3 Study Evaluating V940 (mRNA-4157) In
Combination With KEYTRUDA for Adjuvant Treatment of Patients With
Resected High-Risk (Stage IIB-IV) Melanoma
(Read
Announcement)
Merck and Moderna Announced mRNA-4157 (V940) in Combination With
KEYTRUDA Demonstrated a Statistically Significant and Clinically Meaningful
Improvement in Distant Metastasis-Free Survival in Patients With High-Risk
Stage III/IV Melanoma Following Complete Resection Versus KEYTRUDA
(Read
Announcement)
KEYTRUDA Plus Chemotherapy Significantly Improved Overall Survival
Versus Chemotherapy Alone as First-Line Treatment for Unresectable
Advanced Pleural Mesothelioma
(Read
Announcement)
KEYTRUDA Plus Lenvima Demonstrated Long-Term, Durable Survival Benefit
Versus Sunitinib as First-Line Treatment for Patients With Advanced RCC
(Read
Announcement)
Merck Announced Phase 3 KEYNOTE-A18 Trial Met Primary Endpoint of
Progression-Free Survival (PFS) in Patients With Newly Diagnosed High-Risk
Locally Advanced Cervical Cancer
(Read
Announcement)
KEYTRUDA Plus Trastuzumab and Chemotherapy Met Primary Endpoint of
PFS as First-Line Treatment in Patients With HER2-Positive Advanced Gastric
or Gastroesophageal Junction Adenocarcinoma
(Read
Announcement)
Vaccines
Merck Announced V116, an Investigational, 21-Valent Pneumococcal
Conjugate Vaccine Specifically Designed for Adults, Met Key Immunogenicity
and Safety Endpoints in Two Phase 3 Trials
(Read
Announcement)
Other Pipeline
Updates
FDA Approved New Indication for Merck’s PREVYMIS for Prevention of
Cytomegalovirus Disease in High-Risk Adult Kidney Transplant Recipients
(Read
Announcement)
Merck Presented Phase 2a Data for Efinopegdutide (MK-6024), an
Investigational GLP-1/Glucagon Receptor Co-agonist, in Patients With
Nonalcoholic Fatty Liver Disease, at EASL 2023; Additionally, Efinopegdutide
Was Granted Fast Track Designation by the FDA for the Treatment of
Nonalcoholic Steatohepatitis (NASH)
(Read
Announcement)
Merck Received Positive European Union Committee for Medicinal Products
for Human Use (CHMP) Opinion for Gefapixant
(Read
Announcement)

-- 7 of 11 --

- 8 -
Full-Year 2023 Financial Outlook
The following table summarizes the company’s full-year financial outlook.
Sales* 	$58.6 to $59.6 billion
Non-GAAP Gross margin 2 	Approximately 77%
Non-GAAP Operating expenses 2 ** 	$34.0 to $34.6 billion
Non-GAAP Other (income) expense, net 2 	Approximately $100 million
Non-GAAP Effective tax rate2 *** 	30.5% to 31.5%
Non-GAAP EPS2 **** 	$2.95 to $3.05
Share count (assuming dilution) 	2.55 billion
*Includes approximately $1.0 billion of LAGEVRIO sales. The company does not have any non-GAAP adjustments to sales.
**Includes an aggregate $11.6 billion of R&D expenses related to the Prometheus and Imago BioSciences, Inc. (Imago) acquisitions
and upfront payment for the license and collaboration agreement with Kelun-Biotech (a holding subsidiary of Sichuan Kelun
Pharmaceutical Co., Ltd). Outlook does not assume any additional significant potential business development transactions.
***Includes a negative impact of 15 percentage points from the one-time charge for the acquisition of Prometheus.
****Includes $4.53 of one-time charges related to the Prometheus and Imago acquisitions and upfront payment to Kelun-Biotech.
Merck has not provided a reconciliation of forward-looking non-GAAP gross margin, non-
GAAP operating expenses, non-GAAP other (income) expense, net, non-GAAP effective tax
rate and non-GAAP EPS to the most directly comparable GAAP measures, given it cannot
predict with reasonable certainty the amounts necessary for such a reconciliation, including
intangible asset impairment charges, legal settlements, and gains and losses from investments
in equity securities either owned directly or through ownership interests in investment funds,
without unreasonable effort. These items are inherently difficult to forecast and could have a
significant impact on the company’s future GAAP results.
Merck continues to experience strong global demand for key growth products,
particularly in oncology and vaccines. As a result, Merck is raising and narrowing its full-year
sales outlook. Merck now expects full-year sales to be between $58.6 billion and $59.6 billion,
including a negative impact of foreign exchange of approximately 2 percentage points, at mid-
July 2023 exchange rates. This full-year outlook continues to include approximately $1.0 billion
of LAGEVRIO sales.
Merck’s full-year non-GAAP effective income tax rate is expected to be between 30.5%
and 31.5%, including an unfavorable impact of approximately 15 percentage points from the
non-tax deductible one-time charge for the acquisition of Prometheus.
Merck now expects its full-year non-GAAP EPS to be between $2.95 and $3.05,
including a negative impact of foreign exchange of approximately 5 percentage points, at mid-
July 2023 exchange rates. This revised non-GAAP EPS range reflects the following, which were
not previously included in the outlook:
• 	Additional strength in the business of approximately $0.24 per share.
• 	A charge of $10.2 billion, or $4.02 per share, for the acquisition of Prometheus.
• 	Estimated 2023 expense of approximately $0.14 per share to be incurred to finance the
Prometheus acquisition and to advance the acquired assets.

-- 8 of 11 --

- 9 -
• 	A less than 1%, or approximately $0.02 per share, incremental negative impact of
foreign exchange.
The non-GAAP EPS range excludes acquisition- and divestiture-related costs and costs
related to restructuring programs, as well as income and losses from investments in equity
securities, and a previously disclosed charge related to settlements with certain plaintiffs in the
Zetia antitrust litigation.
Earnings Conference Call
Investors, journalists and the general public may access a live audio webcast of the
earnings conference call on Tuesday, Aug. 1, at 8 a.m. ET via this weblink. A replay of the
webcast, along with the sales and earnings news release, supplemental financial disclosures,
prepared remarks and slides highlighting the results, will be available at www.merck.com.
All participants may join the call by dialing (888) 769-8514 (U.S. and Canada Toll-Free)
or (517) 308-9208 and using the access code 8206435.
About Merck
At Merck, known as MSD outside of the United States and Canada, we are unified
around our purpose: We use the power of leading-edge science to save and improve lives
around the world. For more than 130 years, we have brought hope to humanity through the
development of important medicines and vaccines. We aspire to be the premier research-
intensive biopharmaceutical company in the world – and today, we are at the forefront of
research to deliver innovative health solutions that advance the prevention and treatment of
diseases in people and animals. We foster a diverse and inclusive global workforce and operate
responsibly every day to enable a safe, sustainable and healthy future for all people and
communities. For more information, visit www.merck.com and connect with us on Twitter,
Facebook, Instagram, YouTube and LinkedIn.
Forward-Looking Statement of Merck & Co., Inc., Rahway, N.J., USA
This news release of Merck & Co., Inc., Rahway, N.J., USA (the “company”) includes
“forward-looking statements” within the meaning of the safe harbor provisions of the U.S.
Private Securities Litigation Reform Act of 1995. These statements are based upon the current
beliefs and expectations of the company’s management and are subject to significant risks and
uncertainties. There can be no guarantees with respect to pipeline candidates that the
candidates will receive the necessary regulatory approvals or that they will prove to be
commercially successful. If underlying assumptions prove inaccurate or risks or uncertainties
materialize, actual results may differ materially from those set forth in the forward-looking
statements.
Risks and uncertainties include but are not limited to, general industry conditions and
competition; general economic factors, including interest rate and currency exchange rate
fluctuations; the impact of the global outbreak of novel coronavirus disease (COVID-19); the
impact of pharmaceutical industry regulation and health care legislation in the United States and

-- 9 of 11 --

- 10 -
internationally; global trends toward health care cost containment; technological advances, new
products and patents attained by competitors; challenges inherent in new product development,
including obtaining regulatory approval; the company’s ability to accurately predict future market
conditions; manufacturing difficulties or delays; financial instability of international economies
and sovereign risk; dependence on the effectiveness of the company’s patents and other
protections for innovative products; and the exposure to litigation, including patent litigation,
and/or regulatory actions.
The company undertakes no obligation to publicly update any forward-looking statement,
whether as a result of new information, future events or otherwise. Additional factors that could
cause results to differ materially from those described in the forward-looking statements can be
found in the company’s Annual Report on Form 10-K for the year ended December 31, 2022,
and the company’s other filings with the Securities and Exchange Commission (SEC) available
at the SEC’s Internet site (www.sec.gov).
Appendix
Generic product names are provided below.
Pharmaceutical
BRIDION (sugammadex)
GARDASIL (Human Papillomavirus Quadrivalent [Types 6, 11, 16 and 18] Vaccine,
Recombinant)
GARDASIL 9 (Human Papillomavirus 9-valent Vaccine, Recombinant)
JANUMET (sitagliptin and metformin HCl)
JANUVIA (sitagliptin)
KEYTRUDA (pembrolizumab)
LAGEVRIO (molnupiravir)
Lenvima (lenvatinib)
Lynparza (olaparib)
M-M-R II (Measles, Mumps and Rubella Virus Vaccine Live)
PREVYMIS (letermovir)
PROQUAD (Measles, Mumps, Rubella and Varicella Virus Vaccine Live)
SIMPONI (golimumab)
VARIVAX (Varicella Virus Vaccine Live)
VAXNEUVANCE (Pneumococcal 15-valent Conjugate Vaccine)
Animal Health
BRAVECTO (fluralaner)
###
Media Contacts: 	Investor Contacts:
Robert Josephson
(203) 914-2372
Peter Dannenbaum
(732) 594-1579

-- 10 of 11 --

- 11 -
robert.josephson@merck.com
Michael Levey
(215) 872-1462
michael.levey@merck.com
peter.dannenbaum@merck.com
Steven Graziano
(732) 594-1583
steven.graziano@merck.com

-- 11 of 11 --